Finance fibrillation and research rhythm: do we need a pacemaker?

J Ambul Care Manage

Laboratory for Translational and Outcome Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

Published: June 2008

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JAC.0000314709.65289.72DOI Listing

Publication Analysis

Top Keywords

finance fibrillation
4
fibrillation rhythm
4
rhythm pacemaker?
4
finance
1
rhythm
1
pacemaker?
1

Similar Publications

Aims: We aimed to explore atrial fibrillation (AF)-induced productivity losses in working-age atrial fibrillation patients and to estimate atrial fibrillation-related indirect costs.

Methods: Between 2014 and 2017, the Swiss Atrial Fibrillation prospective cohort study (Swiss-AF) enrolled 217 working-age patients with documented atrial fibrillation. Self-reported changes in professional activity and the reasons thereof were descriptively analysed over 8 years of follow-up or until patients reached the retirement age.

View Article and Find Full Text PDF

Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real-world setting.

Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all-cause mortality.

View Article and Find Full Text PDF

Quantifying years of life lost in Australia: a multiple cause of death analysis.

Int J Epidemiol

December 2024

National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia.

Background: Deaths in Australia and other high-income countries increasingly involve multiple conditions. However, key burden of disease measures typically only use the underlying cause of death (UC). We quantified sex and cause-specific years of life lost (YLL) based on UC compared with a method integrating multiple causes of death.

View Article and Find Full Text PDF

Objective: The administration of amiodarone or lidocaine is recommended during the resuscitation of out-of-hospital cardiac arrest (OHCA) patients presenting with defibrillation-refractory or recurrent ventricular fibrillation or ventricular tachycardia. Our objective was to use 'target trial emulation' methodology to compare the outcomes of patients who received amiodarone or lidocaine during resuscitation.

Methods: Adult, non-traumatic OHCA patients in the ESO Data Collaborative 2018-2023 datasets who experienced OHCA prior to EMS arrival, presented with a shockable rhythm, and received amiodarone or lidocaine during resuscitation were evaluated for inclusion.

View Article and Find Full Text PDF

Introduction: Effective defibrillation is essential to out-of-hospital cardiac arrest (OHCA) survival. International guidelines recommend initial defibrillation energies between 120 and 360 Joules, which has led to widespread practice variation. Leveraging this natural experiment, we aimed to explore the association between initial defibrillation dose and outcome following OHCA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!